---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-114306"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2026-03-18T23:59:59+00:00"
generated_at: "2026-05-15T09:50:12.695323+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Catalyst bench trial for FIRDAPSE patents delayed from March 23 to May 18, 2026

## Summary
- District of New Jersey order delays start of bench trial to May 18, 2026, originally March 23, 2026.
- Trial concerns validity of Orange Book-listed patents for FIRDAPSE expiring 2032, 2034, and 2037.
- Litigation is with Hetero USA, Inc. over Catalyst's proprietary drug FIRDAPSE patents.

## SEC filing metadata
- accession: 0001193125-26-114306
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2026-03-18T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312526114306/0001193125-26-114306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312526114306/d111324d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-114306
- JSON: https://secwatch.observer/filing/0001193125-26-114306.json
- Plain text: https://secwatch.observer/filing/0001193125-26-114306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.